Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

@article{Ford2014DocetaxelVA,
  title={Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.},
  author={Hugo E. R. Ford and Andrea R. Marshall and John A Bridgewater and Tobias Janowitz and Fareeda Y Coxon and Jonathan Charles Wadsley and Wasat Mansoor and David Fyfe and Srinivasan Madhusudan and Gary William Middleton and Daniel Edmund Bryan Swinson and Stephen J. Falk and Ian Chau and David C. Cunningham and Paula Kareclas and Natalie Cook and Jane M. Blazeby and Janet. A. Dunn},
  journal={The Lancet. Oncology},
  year={2014},
  volume={15 1},
  pages={78-86}
}
BACKGROUND Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum and fluoropyrimidines has not shown benefits in health-related quality of life (HRQoL). We assessed whether the addition of docetaxel to active symptom control alone can improve survival and HRQoL for patients. METHODS For this open-labelled, multicentre trial, we recruited patients aged 18 years or older from 30 UK centres. Patients were eligible if they had an advanced… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 102 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 134 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology • 2016

Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.

Jin Li, Shukui Qin, +15 authors Hao Yu
Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2013

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2013

Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research • 2013

Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology • 2013

Similar Papers

Loading similar papers…